ATE84420T1 - Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen. - Google Patents

Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen.

Info

Publication number
ATE84420T1
ATE84420T1 AT87901815T AT87901815T ATE84420T1 AT E84420 T1 ATE84420 T1 AT E84420T1 AT 87901815 T AT87901815 T AT 87901815T AT 87901815 T AT87901815 T AT 87901815T AT E84420 T1 ATE84420 T1 AT E84420T1
Authority
AT
Austria
Prior art keywords
alpha
compositions
melanocytes
stimulation
methods
Prior art date
Application number
AT87901815T
Other languages
English (en)
Inventor
Victor J Hruby
Mac E Hadley
Robert Dorr
Norman Levine
Elizabeth Sugg
Wayne L Cody
Original Assignee
University Patents Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Patents Inc filed Critical University Patents Inc
Application granted granted Critical
Publication of ATE84420T1 publication Critical patent/ATE84420T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/04—Preparations for care of the skin for chemically tanning the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT87901815T 1986-02-03 1987-01-23 Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen. ATE84420T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82516286A 1986-02-03 1986-02-03
PCT/US1987/000226 WO1987004623A1 (en) 1986-02-03 1987-01-23 Method of stimulating melanocytes by topical application of analogs of alpha-msh, and compositions for use in same
EP87901815A EP0259440B1 (de) 1986-02-03 1987-01-23 Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen

Publications (1)

Publication Number Publication Date
ATE84420T1 true ATE84420T1 (de) 1993-01-15

Family

ID=25243274

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87901815T ATE84420T1 (de) 1986-02-03 1987-01-23 Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen.

Country Status (11)

Country Link
US (2) US4918055A (de)
EP (1) EP0259440B1 (de)
KR (1) KR900005903B1 (de)
AT (1) ATE84420T1 (de)
AU (1) AU597630B2 (de)
CA (1) CA1282324C (de)
DE (1) DE3783541T2 (de)
DK (1) DK518187A (de)
IE (1) IE60883B1 (de)
NZ (1) NZ233248A (de)
WO (1) WO1987004623A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2711549B2 (ja) * 1987-06-01 1998-02-10 圭吉 杉山 白髪防止・改善用組成物
US5049547A (en) * 1988-02-11 1991-09-17 University Patents, Inc. Composition for stimulating integumental melanocytes
US4874744A (en) * 1989-03-13 1989-10-17 University Of Cincinnati Method of using melanocyte stimulating hormone as dermatis treatment
EP0389950A1 (de) * 1989-03-23 1990-10-03 Lion Corporation Inhibitor des melanocytenstimulierenden Hormons und dieses enthaltendes, äusserlich anwendbares Präparat
US5470577A (en) * 1993-07-07 1995-11-28 Trustees Of Boston University Stimulation of tanning by DNA fragments or single-stranded DNA
US5726156A (en) * 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5420109A (en) 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
US5786332A (en) * 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
US6001812A (en) * 1995-04-28 1999-12-14 Societe L'oreal S.A. Modulating body/cranial hair growth with derivatives of the α-type melanocyte-stimulating hormone
FR2733421B1 (fr) * 1995-04-28 1997-06-06 Oreal Utilisation de derives de l'hormone stimulatrice des melanocytes de type alpha pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
US5767152A (en) * 1995-05-04 1998-06-16 Nielsen; Thor Bagger Composition and methods for stimulating hair growth
US6696417B1 (en) 1997-11-21 2004-02-24 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Skin and hair darkening composition
GB9801191D0 (en) * 1998-01-20 1998-03-18 Unilever Plc Skin and hair darkening composition
US6603058B1 (en) 1998-12-09 2003-08-05 Oklahoma Medical Research Foundation Non-human animal model for obesity and uses thereof
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
CA2359636A1 (en) * 1999-01-22 2000-07-27 Andrew W. Taylor Activation of regulatory t cells by alpha-melanocyte stimulating hormone
WO2000059527A1 (en) * 1999-03-24 2000-10-12 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
US7402559B2 (en) 1999-03-24 2008-07-22 Msh Pharma, Incorporated Composition and method of treatment for urogenital conditions
US6800291B1 (en) * 1999-03-24 2004-10-05 Zengen, Inc. Uro-genital condition treatment system
US7169603B2 (en) * 2000-07-14 2007-01-30 Mgi Pharma Biologics, Inc. α-MSH related compounds and methods of use
WO2003072072A1 (en) * 2002-02-26 2003-09-04 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method of stimulation of melanin production and induction of skin tanning
DE10228837B4 (de) * 2002-06-27 2016-01-07 Elfriede Rauch Hautkosmetische Zusammensetzung und Verwendung der Zusammensetzung als Hautbräunungsmittel
DK1689349T3 (da) * 2003-11-24 2013-12-02 Clinuvel Pharmaceuticals Ltd Fremgangsmåde til induktion af melanogenese i mennesker med variante MC1R-alleler
US9345911B2 (en) * 2004-08-04 2016-05-24 Clinuvel Pharmaceuticals Limited Methods of inducing melanogenesis in a subject
JP5449673B2 (ja) 2004-10-08 2014-03-19 クリヌベール、ファーマスーティカルズ、リミテッド 対象者におけるメラニン形成を誘導するための組成物および方法
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
WO2006052468A2 (en) 2004-10-27 2006-05-18 University Of Denver Adrenocorticotropic hormone analogs and related methods
WO2008015342A2 (fr) * 2006-08-03 2008-02-07 Societe D'extraction Des Principes Actifs Sa (Vincience) Utilisation d'un extrait vegetal en tant qu'agent actif pour augmenter la synthese de melanine dans les melanocytes
AU2007291943B2 (en) 2006-08-28 2013-11-14 Clinuvel Pharmaceuticals Limited Method for reducing incidence or rate of development of skin cancers and related conditions
WO2008025094A1 (en) 2006-08-31 2008-03-06 Clinuvel Pharmaceuticals Limited Method of treatment of photodermatoses
CA2666418A1 (en) * 2006-10-13 2008-05-29 Reliance Life Sciences Pvt. Ltd. Cultured melanocytes on biopolymers
US20110130705A1 (en) 2008-03-27 2011-06-02 Clinuvel Pharmaceuticals Limited Therapy for vitiligo
EP2350031A2 (de) 2008-08-20 2011-08-03 Ensemble Therapeutics Corporation Makrocyclische verbindungen zur inhibierung des tumornekrosefaktors alpha
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
US9610461B2 (en) 2012-03-15 2017-04-04 Galderma Research & Development Combination of a MC1R receptor agonist and UVB for the treatment and/or prevention of pigmentation disorders
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US20140271742A1 (en) * 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Skin tanning using peptides and other compositions
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
WO2015063102A1 (en) 2013-10-28 2015-05-07 Clinuvel Ag Alpha-msh analogues for use in bullous disease
WO2015063099A1 (en) 2013-10-28 2015-05-07 Clinuvel Ag Alpha-msh analogues for use in the treatment of hailey-hailey disease
WO2015067503A1 (en) 2013-11-07 2015-05-14 Clinuvel Ag Alpha-msh analogues for use in the treatment of psoriasis
WO2016048246A1 (en) * 2014-09-25 2016-03-31 Nanyang Technological University Targeting of melanocytes for delivering therapeutic or diagnostic agents using protein nanocages
WO2016066702A1 (en) 2014-10-28 2016-05-06 Clinuvel Ag Inflammatory disease
US20170304406A1 (en) 2014-10-28 2017-10-26 Clinuvel Ag New indication for alpha-msh analogues
WO2016195476A1 (en) 2015-05-29 2016-12-08 Erasmus University Medical Center Rotterdam Treatment of cardiac arrhythmias
CN106265134B (zh) * 2016-03-17 2019-02-19 哈尔滨源茂达生物技术有限公司 一种多肽美白修复精华液及其制备方法
EP3573645B1 (de) 2017-02-01 2024-03-13 Vallaurix Mc S.A.R.L. Alpha-msh-analoga zur behandlung von xeroderma pigmentosum
WO2025253347A1 (en) * 2024-06-07 2025-12-11 Vimela Therapeutics, Inc. Topical delivery of melanocortin-1 receptor agonists formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2158123A1 (de) * 1970-12-02 1972-06-08 Ciba-Geigy Ag, Basel (Schweiz) Neue pharmazeutische Präparate
US4457864A (en) * 1981-10-23 1984-07-03 University Patents, Inc. Synthetic analogues of α-melanotropin
US4485039A (en) * 1982-06-11 1984-11-27 University Patents, Inc. Synthetic analogues of α-melanotropin
DE3623019A1 (de) * 1986-07-09 1988-01-21 Dieter Prof Dr Dr Aderhold Melanotropin als therapeutischer wirkstoff

Also Published As

Publication number Publication date
WO1987004623A1 (en) 1987-08-13
EP0259440A4 (de) 1989-11-07
NZ233248A (en) 1993-01-27
EP0259440A1 (de) 1988-03-16
AU597630B2 (en) 1990-06-07
CA1282324C (en) 1991-04-02
US4918055A (en) 1990-04-17
IE60883B1 (en) 1994-08-24
US4866038A (en) 1989-09-12
DK518187A (da) 1987-12-02
DE3783541D1 (de) 1993-02-25
DE3783541T2 (de) 1993-06-17
KR880700670A (ko) 1988-04-11
IE870236L (en) 1987-08-03
DK518187D0 (da) 1987-10-02
EP0259440B1 (de) 1993-01-13
KR900005903B1 (ko) 1990-08-16
AU7082887A (en) 1987-08-25

Similar Documents

Publication Publication Date Title
ATE84420T1 (de) Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen.
FI871668A7 (fi) Menetelmä amantadiinin ja selegiliinin synergistisen yhdistelmän valmistamiseksi.
ATE115962T1 (de) Verfahren für umwandlung von menschlichem insulin-vorläufer in menschliches insulin.
DE68919637D1 (de) Verfahren und Einrichtung zur Sprachsynthese durch Überdeckung und Summierung von Wellenformen.
DE3750323D1 (de) Verfahren zur Ortung mittels Satelliten.
DE3888205D1 (de) Verfahren zur behandlung von lungenaffektionen und zubereitungen dafür.
ATA225280A (de) Schiene zur reposition und ruhigstellung von finger- und mittelhandfrakturen sowie verfahren zur herstellung der schiene
ATA318081A (de) Verfahren zur herstellung von topischen verfahren zur herstellung von topischen pharmazeutischen zubereitungen pharmazeutischen zubereitungen
DE3778996D1 (de) Verfahren zur herstellung von erdalkalimetalltitanaten in pulverform.
DE69001248D1 (de) Verfahren und zusammensetzungen zur isolation von menschlichem relaxin.
AT372856B (de) Verfahren zur herstellung von humanem relaxin
ATA58686A (de) Verfahren zur herstellung von polyurethanen, insbesondere von polyurethanelastomeren, sowie verfahren zur radikalischen polymerisation
DE3688168D1 (de) Epidermiszellenextrakte und verfahren zur verbesserung der wundheilung und zur regenerierung der epidermis.
DE3770224D1 (de) Verfahren zur herstellung von hypofluoriten und bis-hypofluoriten.
AT388100B (de) Verfahren zur herstellung von synergistisch wirkenden antibiotikakombinationen
DE3678189D1 (de) Verfahren zur herstellung von aminoalkoholen durch elektrochemische reduktion von nitroalkoholen.
DE3673762D1 (de) Verfahren zur herstellung eines ammoniak-komplexes von zink-bis-dithiocarbamat.
DE3574974D1 (de) Verfahren zur herstellung von milbemycinderivaten und einige in diesem verfahren verwendete derivate.
ATA247687A (de) Verfahren zur herstellung von 5-aryliden- und -alkylidensubstituierten hydantoinen
DE3580867D1 (de) Verfahren zur herstellung von substituierten halomethyl-s-triazinen.
NO874962L (no) Totrinnsmetode for indolent saarheling og vandig medium og topisk salve benyttet i denne forbindelse.
ATE90928T1 (de) Verfahren zur darstellung von verbundkoerpern.
ATA257786A (de) Verfahren zur herstellung galenischer zubereitungen
ATE55055T1 (de) Therapeutische brausemischung sowie verfahren zu deren herstellung.
AT379588B (de) Verfahren zur herstellung von gamma-glutamyl -taurin sowie dessen salzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties